台股 » 美時 » 個股財報 » 每月營收

美時

(1795)
可現股當沖
  • 股價
    223.5
  • 漲跌
    ▲1.5
  • 漲幅
    +0.68%
  • 成交量
    1,800
  • 產業
    上市 生技醫療類股 ▼0.28%
  • 本地時間:14:30(已收盤)

    626人加入追蹤

    立即追蹤

美時 (1795) 財務報表-每月營收
月營收報表

因應IFRSs國際會計準則,本報表在2013年以前為「個別營收」,2013年以後為「合併營收」。

美時 (1795) 月營收分析比較圖

Created with Highstock 1.3.7美時 (1795)嗨投資 histock.tw單月營收去年同月營收月收盤價2020/012021/012022/012023/012024/012025/0101,000,0002,000,0003,000,0004,000,0000100200300400
Created with Highstock 1.3.7美時 (1795)嗨投資 histock.tw增減分界單月月增率%月收盤價2020/012021/012022/012023/012024/012025/01-10001002003000100200300400
Created with Highstock 1.3.7美時 (1795)嗨投資 histock.tw增減分界單月年增率%月收盤價2020/012021/012022/012023/012024/012025/01-10001002003000100200300400

美時 (1795) 月營收報表

年度/月份營業收入(單位:千元)累計營業收入(單位:千元)
單月營收去年同月營收單月月增率單月年增率累計營收去年累計營收累積年增率
2025/051,129,4131,552,630-56.1%-27.3%8,432,5387,827,1027.7%
2025/042,573,3412,076,32861.7%23.9%7,303,1256,274,47216.4%
2025/031,591,7271,150,52964.7%38.3%4,729,7844,198,14412.7%
2025/02966,7121,051,899-55.5%-8.1%3,138,0573,047,6153%
2025/012,171,3451,995,71648.4%8.8%2,171,3451,995,7168.8%
2024/121,463,3011,372,42538%6.6%18,584,23016,957,9709.6%
2024/111,060,6551,135,020-43.7%-6.6%17,120,93015,585,5509.9%
2024/101,884,995911,65358.8%106.8%16,060,27014,450,53011.1%
2024/091,186,8211,100,388-10.4%7.8%14,175,28013,538,8704.7%
2024/081,325,3381,184,833-51.3%11.9%12,988,46012,438,4904.4%
2024/072,722,0452,287,950144.4%19%11,663,12011,253,6503.6%
2024/061,113,9701,103,110-28.3%1%8,941,0728,965,703-0.3%
2024/051,552,6301,321,517-25.2%17.5%7,827,1027,862,593-0.4%
2024/042,076,3282,017,21680.5%2.9%6,274,4726,541,075-4.1%
2024/031,150,5291,430,1859.4%-19.5%4,198,1444,523,860-7.2%
2024/021,051,8991,085,919-47.3%-3.1%3,047,6153,093,675-1.5%
2024/011,995,7162,007,75645.4%-0.6%1,995,7162,007,756-0.6%
2023/121,372,4251,270,97620.9%8%16,957,97014,632,77015.9%
2023/111,135,0201,071,32424.5%5.9%15,585,55013,361,80016.6%
2023/10911,653829,290-17.1%9.9%14,450,53012,290,47017.6%
2023/091,100,3883,348,921-7.1%-67.1%13,538,87011,461,18018.1%
2023/081,184,833996,806-48.2%18.9%12,438,4908,112,26153.3%
2023/072,287,9501,043,645107.4%119.2%11,253,6507,115,45458.2%
2023/061,103,1101,040,734-16.5%6%8,965,7036,071,80947.7%
2023/051,321,517870,540-34.5%51.8%7,862,5935,031,06956.3%
2023/042,017,216999,15141%101.9%6,541,0754,160,52957.2%
2023/031,430,1851,186,65231.7%20.5%4,523,8603,161,37743.1%
2023/021,085,9191,028,926-45.9%5.5%3,093,6751,974,72556.7%
2023/012,007,756945,80058%112.3%2,007,756945,800112.3%
2022/121,270,976914,16218.6%39%14,632,77012,649,19015.7%
2022/111,071,324986,36729.2%8.6%13,361,80011,700,91014.2%
2022/10829,290868,252-75.2%-4.5%12,290,47010,714,54014.7%
2022/093,348,9211,012,862236%230.6%11,461,1809,846,28616.4%
2022/08996,806936,958-4.5%6.4%8,112,2618,833,317-8.2%
2022/071,043,6451,107,8530.3%-5.8%7,115,4487,896,359-9.9%
2022/061,040,7341,150,11819.5%-9.5%6,071,8036,788,506-10.6%
〈焦點股〉美時Bosutinib獲台灣TFDA核准上市 股價走揚攻季線Anue鉅亨-16天前
美時與上海復宏漢霖合作 將在韓國銷售抗 PD-1抗體新藥UDN聯合新聞網-2025/04/25
美時 相關文章